Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996809166> ?p ?o ?g. }
- W2996809166 endingPage "549" @default.
- W2996809166 startingPage "539" @default.
- W2996809166 abstract "Abstract Background We sought to ascertain the immune effector function of pembrolizumab within the glioblastoma (GBM) microenvironment during the therapeutic window. Methods In an open-label, single-center, single-arm phase II “window-of-opportunity” trial in 15 patients with recurrent (operable) GBM receiving up to 2 pembrolizumab doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities occurred, immune responses were evaluated within the tumor. Results No treatment-related deaths occurred. Overall median follow-up time was 50 months. Of 14 patients monitored, 10 had progressive disease, 3 had a partial response, and 1 had stable disease. Median progression-free survival (PFS) was 4.5 months (95% CI: 2.27, 6.83), and the 6-month PFS rate was 40%. Median overall survival (OS) was 20 months, with an estimated 1-year OS rate of 63%. GBM patients’ recurrent tumors contained few T cells that demonstrated a paucity of immune activation markers, but the tumor microenvironment was markedly enriched for CD68+ macrophages. Conclusions Immune analyses indicated that pembrolizumab anti–programmed cell death 1 (PD-1) monotherapy alone can’t induce effector immunologic response in most GBM patients, probably owing to a scarcity of T cells within the tumor microenvironment and a CD68+ macrophage preponderance." @default.
- W2996809166 created "2020-01-10" @default.
- W2996809166 creator A5005282702 @default.
- W2996809166 creator A5007445074 @default.
- W2996809166 creator A5010502061 @default.
- W2996809166 creator A5012403937 @default.
- W2996809166 creator A5013307500 @default.
- W2996809166 creator A5017578103 @default.
- W2996809166 creator A5019360674 @default.
- W2996809166 creator A5024476694 @default.
- W2996809166 creator A5026152840 @default.
- W2996809166 creator A5026241338 @default.
- W2996809166 creator A5030122856 @default.
- W2996809166 creator A5034269049 @default.
- W2996809166 creator A5040657587 @default.
- W2996809166 creator A5046338327 @default.
- W2996809166 creator A5047117233 @default.
- W2996809166 creator A5047330975 @default.
- W2996809166 creator A5050191637 @default.
- W2996809166 creator A5054514877 @default.
- W2996809166 creator A5055183757 @default.
- W2996809166 creator A5058544711 @default.
- W2996809166 creator A5062153042 @default.
- W2996809166 creator A5064966874 @default.
- W2996809166 creator A5065920207 @default.
- W2996809166 creator A5069434459 @default.
- W2996809166 creator A5071033599 @default.
- W2996809166 creator A5077658566 @default.
- W2996809166 creator A5079081497 @default.
- W2996809166 creator A5087117639 @default.
- W2996809166 creator A5087883229 @default.
- W2996809166 creator A5091806633 @default.
- W2996809166 date "2019-11-22" @default.
- W2996809166 modified "2023-10-13" @default.
- W2996809166 title "Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages" @default.
- W2996809166 cites W1631320694 @default.
- W2996809166 cites W1815157104 @default.
- W2996809166 cites W1881610795 @default.
- W2996809166 cites W1959427476 @default.
- W2996809166 cites W1980485314 @default.
- W2996809166 cites W2047230902 @default.
- W2996809166 cites W2084894578 @default.
- W2996809166 cites W2092772483 @default.
- W2996809166 cites W2105100844 @default.
- W2996809166 cites W2111137187 @default.
- W2996809166 cites W2114850139 @default.
- W2996809166 cites W2125493895 @default.
- W2996809166 cites W2125521995 @default.
- W2996809166 cites W2136859769 @default.
- W2996809166 cites W2196188512 @default.
- W2996809166 cites W2220215167 @default.
- W2996809166 cites W2262102254 @default.
- W2996809166 cites W2267547820 @default.
- W2996809166 cites W2280099094 @default.
- W2996809166 cites W2294356527 @default.
- W2996809166 cites W2338890931 @default.
- W2996809166 cites W2435243879 @default.
- W2996809166 cites W2462122693 @default.
- W2996809166 cites W2463645998 @default.
- W2996809166 cites W2471873673 @default.
- W2996809166 cites W2512255557 @default.
- W2996809166 cites W2584371626 @default.
- W2996809166 cites W2591531756 @default.
- W2996809166 cites W2600281432 @default.
- W2996809166 cites W2615301036 @default.
- W2996809166 cites W2774491730 @default.
- W2996809166 cites W2790035192 @default.
- W2996809166 cites W2800345821 @default.
- W2996809166 cites W2887361912 @default.
- W2996809166 cites W2896996016 @default.
- W2996809166 cites W2911752971 @default.
- W2996809166 cites W2913623258 @default.
- W2996809166 cites W2951880440 @default.
- W2996809166 doi "https://doi.org/10.1093/neuonc/noz185" @default.
- W2996809166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7158647" @default.
- W2996809166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31755915" @default.
- W2996809166 hasPublicationYear "2019" @default.
- W2996809166 type Work @default.
- W2996809166 sameAs 2996809166 @default.
- W2996809166 citedByCount "90" @default.
- W2996809166 countsByYear W29968091662019 @default.
- W2996809166 countsByYear W29968091662020 @default.
- W2996809166 countsByYear W29968091662021 @default.
- W2996809166 countsByYear W29968091662022 @default.
- W2996809166 countsByYear W29968091662023 @default.
- W2996809166 crossrefType "journal-article" @default.
- W2996809166 hasAuthorship W2996809166A5005282702 @default.
- W2996809166 hasAuthorship W2996809166A5007445074 @default.
- W2996809166 hasAuthorship W2996809166A5010502061 @default.
- W2996809166 hasAuthorship W2996809166A5012403937 @default.
- W2996809166 hasAuthorship W2996809166A5013307500 @default.
- W2996809166 hasAuthorship W2996809166A5017578103 @default.
- W2996809166 hasAuthorship W2996809166A5019360674 @default.
- W2996809166 hasAuthorship W2996809166A5024476694 @default.
- W2996809166 hasAuthorship W2996809166A5026152840 @default.
- W2996809166 hasAuthorship W2996809166A5026241338 @default.
- W2996809166 hasAuthorship W2996809166A5030122856 @default.
- W2996809166 hasAuthorship W2996809166A5034269049 @default.